XML 60 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Quarterly Consolidated Financial Data (Unaudited)
12 Months Ended
Dec. 31, 2014
Quarterly Consolidated Financial Data (Unaudited)  
Quarterly Consolidated Financial Data (Unaudited)

 

12. Quarterly Consolidated Financial Data (Unaudited)

 

 

 

Quarter Ended

 

 

 

March 31,
2014

 

June 30,
2014

 

September 30,
2014

 

December 31,
2014

 

 

 

(dollars in thousands, except share and per share data)

 

Revenues

 

$

 

$

 

$

 

$

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Research and Development

 

13,299

 

24,479

 

20,946

 

24,550

 

Purchased in-process research and development

 

 

 

 

 

 

General and administrative

 

3,178

 

2,279

 

2,506

 

3,041

 

Loss from operations

 

(16,477

)

(26,758

)

(23,452

)

(27,591

)

 

 

 

 

 

 

 

 

 

 

Other income

 

 

 

 

 

 

 

 

 

Amortization of deferred financing costs

 

 

 

 

(411

)

Interest and investment income/(expense), net(includes interest expense of $2,500 on Senior Convertible Debentures for year 2014)

 

29

 

(1

)

19

 

(2,511

)

Tax credits

 

 

83

 

 

 

Change in fair value of derivative instruments—warrants

 

223

 

756

 

425

 

(42

)

Total other income/(loss)

 

252

 

838

 

444

 

(2,964

)

Net Loss

 

$

(16,225

)

$

(25,920

)

$

(23,008

)

(30,555

)

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic and diluted (a)

 

92,056,124

 

94,069,703

 

94,738,048

 

96,190,332

 

Net loss per Common Share, basic and diluted(a):

 

$

(0.18

)

$

(0.28

)

$

(0.24

)

(0.32

)

 

(a)

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.

 

 

 

Quarter Ended

 

 

 

March 31,
2013

 

June 30,
2013

 

September 30,
2013

 

December 31,
2013

 

 

 

(dollars in thousands, except per share data)

 

Revenues

 

$

 

$

 

$

 

$

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Research and Development

 

14,344

 

9,055

 

10,782

 

16,449

 

General and administrative

 

3,278

 

2,803

 

2,692

 

2,908

 

Loss from operations

 

(17,622

)

(11,858

)

(13,474

)

(19,357

)

Other income

 

 

 

 

 

 

 

 

 

Interest and investment income

 

17

 

16

 

14

 

11

 

Interest expense

 

 

 

 

(21

)

Change in fair value of derivative instruments—warrants

 

(1,093

)

1,803

 

(77

)

(484

)

Total other (loss)/income

 

(1,076

)

1,819

 

(63

)

(494

)

Net Loss

 

$

(18,698

)

$

(10,039

)

$

(13,537

)

$

(19,851

)

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic and diluted

 

72,789,006

 

87,482,939

 

90,182,115

 

90,182,115

 

Net loss per common share—basic and diluted(a):

 

$

(0.26

)

$

(0.11

)

$

(0.15

)

$

(0.22

)

 

(a)

Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.